Teriflunomide tablets are used for the treatment of patients with relapsing forms of multiple sclerosis.
"This approval reinforces our capability in successfully developing and commercializing a differentiated product portfolio for the U.S. market," Concord Biotech said in a statement.
According to IQVIA, the market size of Teriflunomide tablets is approximately $402 million in the US, and the global market size is approximately $908 million, indicating significant opportunities for expansion in the US and the global market.
Concord Biotech is involved in manufacturing fermentation and semi-synthetic biopharmaceutical APIs with immunosuppressants as its key therapeutic segment.
The company's consolidated net profit fell 2% to Rs 75.9 crore in Q3 FY25 compared with Rs 77.6 crore in Q3 FY24. Revenue from operations increased 1% year-on-year (YoY) to Rs 244.2 crore in Q3 FY25.
The scrip shed 0.17% to currently trade at Rs 1595.10 on the BSE.